ABSTRACT
The municipal sewage carries the new coronavirus (SARS-CoV-2), shed by COVID-19 patients, to wastewater treatment plants. Proper wastewater treatment can provide an important barrier for preventing uncontrolled discharged of the virus into the environment. However, the role of the different wastewater treatment stages in reducing virus concentrations was, thus far, unknown. In this work, we quantified SARS-CoV-RNA in the raw sewage and along the main stages of the wastewater process from two different plants in Israel during this COVID-19 outbreak. We found that ca. 2 Log removal could be attained after primary and secondary treatment. Despite this removal, significant concentrations of SARS-CoV-RNA (>100 copies per mL) could still be detected in the treated wastewater. However, after treatment by chlorination, SARS-CoV-RNA was detected only once, likely due to insufficient chlorine dose. Our results highlight the need to protect wastewater treatment plants operators, as well as populations living near areas of wastewater discharge, from the risk of infection. In addition, our results emphasize the capabilities and limitations of the conventional wastewater treatment process in reducing SARS-CoV-RNA concentration, and present preliminary evidence for the importance of tertiary treatment and chlorination in reducing SARA-CoV-2 dissemination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We would like to thank funding from Ben Gurion University, The Corona Challenge Covid-19 (https://in.bgu.ac.il/en/corona-challenge/Pages/default.aspx) and funding from the Israeli ministry of Health
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No oversight was required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data is given in the manuscript and in the Supplementary Information file
